Biotech Values

[oc631]

I’m inclined to agree—i.e. I do not expect VRUS to submit an NDA in genotype-2/3 based on only the phase-2 data. However, oc631 has called everything correctly in the HCV arena to date, and he thinks this might be doable; for this reason alone, we should not dismiss the idea out of hand.

I hadn't gone down on record saying this was going to happen. I posed the scenario and was looking for input (Thanks Idit). If the stellar results I proposed in my prior post happens I am quite comfortable saying there will be a NDA filing next year in that subgroup.